An incretin mimetic, such as exenatide (Byetta), is used to improve glycemic control
in people with Type 2 diabetes by reducing fasting and postprandial glucose concentrations.
An incretin mimetic is indicated as adjunctive therapy to individuals who are taking
metformin or a combination of other oral agents. Use of an incretin mimetic in conjunction
with a sulfonylurea has an increased risk of hypoglycemia.
Incretin mimetics are not insulin and can be used without an exemption.
Certification/Recertification — Incretin Mimetic
No recommended time frame
You should not certify the driver until the treatment has been shown to be adequate/effective,
safe, and stable.
Maximum certification — 1 year
NOTE: The Federal Motor Carrier Safety Administration (FMCSA) recommends
frequent monitoring determined on a case-by-case basis.
Recommend to certify if:
The driver with diabetes mellitus who uses an incretin mimetic:
- Meets all the physical qualification standards.
- Has a treatment plan that manages the disease and does not:
- Include the use of insulin.
- Have side effects that interfere with safe driving.
Recommend not to certify if:
As a medical examiner, you believe that the nature and severity of the medical condition
and/or the treatment of the driver endangers the safety and health of the driver
and the public.
FMCSA recommends that a driver taking an incretin mimetic provide a written statement
from the treating health care professional. The written statement should:
- Describe driver tolerance to the medication.
- Indicate how frequently the driver is monitored for adequate blood
- Include efficacy of treatment.
FMCSA recommends frequent monitoring of the driver who is taking an incretin mimetic.